This gap exists because real-world adherence is imperfect, escalation timing is variable, and lifestyle factors are uncontrolled
Patients should contact their healthcare provider promptly if they experience: Severe, persistent abdominal pain that worsens or differs from typical bloating Inability to pass gas or have bowel movements (possible obstruction) Persistent vomiting that prevents adequate hydration or medication adherence Unintentional weight loss beyond expected therapeutic effects Blood in stool or black, tarry stools Fever accompanying gastrointestinal symptoms Right upper quadrant pain or yellowing of skin/eyes (possible gallbladder disease) Severe constipation with abdominal distension (possible ileus/obstruction) Signs of dehydration (excessive thirst, dark urine, dizziness) These symptoms may indicate complications such as pancreatitis, gallbladder disease, bowel obstruction, or acute kidney injuryall noted in FDA prescribing information as potential risks
Patients should not discontinue statins in favour of GLP-1 therapy for cholesterol management without explicit guidance from their healthcare provider, as this could compromise cardiovascular risk reduction
The Aetna Standard Plan covers name-brand Wegovy, Saxenda, Zepbound, and Qsymia, and generic diethylpropion
